Sarepta Therapeutics (SRPT) Tops Q2 EPS by 25c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments
August 5, 2020 4:05 PM EDTNet product sales of $111.3 million, an 18% increase over same quarter of prior year
CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2020.
I am pleased to report that, notwithstanding the distracting nature of the COVID-19 pandemic, Sarepta has continued to serve our patient community, achieving net product sales of $111.3 million, an 18% increase over the same quarter last year. And even as the majority of our workforce continued in a... More
